Skip to main content
. 2023 Jul 18;37(9):1792–1801. doi: 10.1038/s41375-023-01950-9

Fig. 5. CRISPR-Cas9- mediated RUNX1-RUNX1T1 disruption and mRNA expression downregulation in AML t(8;21) patient cells.

Fig. 5

A PCR analysis of CRISPR-Cas9 cleavage products from AML t(8;21) patient 4 cells following electroporation of RNPs (RX1-RX2-RXT1-RXT2). Theoretical PCR product sizes (bp) RX1-RX2-RXT1-RXT2 = 296, 391, 577 and 672; no guides: 24,416. B RUNX1-RUNX1T1 fusion gene mRNA expression in a bone marrow sample (patient 1) and peripheral blood sample (patient 2) from two AML t(8;21) patients. The RUNX1-RUNX1T1 mRNA levels were measured by RT-qPCR. Bars indicate mean of three technical replicates with error bars indicating s.e.m. Patient 1 **p = 0.0091, Patient 2 ***p = 0.0009, Kasumi-1 ****p < 0.0001.